Strategic Analyst Upgrades Fuel Optimism for Nuvalent Recent analyst upgrades, including a move from UBS to a 'Buy' rating with a $100 price target, are boosting confidence in Nuvalent’s prospects. The company’s clinical pipeline, especially for non-small cell lung cancer, and progress toward pivotal data releases in 2025 are attracting attention from both investors and Wall Street.12